Eurobio Scientific Société anonyme (ALERS.PA)
EUR 25.3
(1.2%)
EUR 25.3
(1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 141.15 Million EUR | -10.52% |
| 2022 | 157.74 Million EUR | 221.93% |
| 2021 | 49 Million EUR | -23.97% |
| 2020 | 64.45 Million EUR | 45.03% |
| 2019 | 44.44 Million EUR | 10.35% |
| 2018 | 40.27 Million EUR | 0.99% |
| 2017 | 39.88 Million EUR | 102.84% |
| 2016 | 19.66 Million EUR | 58.52% |
| 2015 | 12.4 Million EUR | -1.16% |
| 2014 | 12.54 Million EUR | -2.34% |
| 2013 | 12.85 Million EUR | -8.17% |
| 2012 | 13.99 Million EUR | 246.7% |
| 2011 | 4.03 Million EUR | -66.56% |
| 2010 | 12.07 Million EUR | 8.83% |
| 2009 | 11.09 Million EUR | -44.84% |
| 2008 | 20.1 Million EUR | 3.0% |
| 2007 | 19.52 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 134.94 Million EUR | 0.0% |
| 2023 Q2 | 138 Million EUR | 0.0% |
| 2023 FY | 141.15 Million EUR | -10.52% |
| 2023 Q4 | 141.15 Million EUR | 0.0% |
| 2022 Q4 | 157.74 Million EUR | 0.0% |
| 2022 FY | 157.74 Million EUR | 221.93% |
| 2022 Q2 | 45.1 Million EUR | 0.0% |
| 2021 Q4 | 49 Million EUR | 0.0% |
| 2021 FY | 49 Million EUR | -23.97% |
| 2021 Q2 | 46.01 Million EUR | 0.0% |
| 2020 FY | 64.45 Million EUR | 45.03% |
| 2020 Q4 | 64.45 Million EUR | 0.0% |
| 2020 Q2 | 56.54 Million EUR | 0.0% |
| 2019 Q2 | 38.48 Million EUR | 0.0% |
| 2019 Q4 | 44.44 Million EUR | 0.0% |
| 2019 FY | 44.44 Million EUR | 10.35% |
| 2018 Q4 | 40.27 Million EUR | 0.0% |
| 2018 FY | 40.27 Million EUR | 0.99% |
| 2018 Q2 | 34.81 Million EUR | 0.0% |
| 2017 Q4 | 39.88 Million EUR | 0.0% |
| 2017 FY | 39.88 Million EUR | 102.84% |
| 2017 Q2 | 35.1 Million EUR | 0.0% |
| 2016 Q4 | 19.66 Million EUR | 0.0% |
| 2016 Q2 | 11.85 Million EUR | 0.0% |
| 2016 FY | 19.66 Million EUR | 58.52% |
| 2015 FY | 12.4 Million EUR | -1.16% |
| 2015 Q4 | 12.4 Million EUR | 0.0% |
| 2015 Q2 | 13.28 Million EUR | 0.0% |
| 2014 Q4 | 12.54 Million EUR | 0.0% |
| 2014 FY | 12.54 Million EUR | -2.34% |
| 2014 Q2 | 12.06 Million EUR | 0.0% |
| 2013 Q2 | 12.76 Million EUR | 0.0% |
| 2013 FY | 12.85 Million EUR | -8.17% |
| 2013 Q4 | 12.85 Million EUR | 0.0% |
| 2012 Q4 | 13.99 Million EUR | 300.0% |
| 2012 Q1 | 3.49 Million EUR | -13.32% |
| 2012 FY | 13.99 Million EUR | 246.7% |
| 2012 Q2 | 5.27 Million EUR | 50.85% |
| 2012 Q3 | 3.49 Million EUR | -33.71% |
| 2011 Q1 | 1 Million EUR | -91.64% |
| 2011 FY | 4.03 Million EUR | -66.56% |
| 2011 Q4 | 4.03 Million EUR | 300.0% |
| 2011 Q3 | 1 Million EUR | -91.81% |
| 2011 Q2 | 12.31 Million EUR | 1120.71% |
| 2010 Q1 | 3.01 Million EUR | -72.79% |
| 2010 Q2 | 12.52 Million EUR | 315.01% |
| 2010 Q3 | 3.01 Million EUR | -75.9% |
| 2010 Q4 | 12.07 Million EUR | 300.0% |
| 2010 FY | 12.07 Million EUR | 8.83% |
| 2009 Q4 | 11.09 Million EUR | 300.0% |
| 2009 Q3 | 2.77 Million EUR | 0.0% |
| 2009 Q2 | 2.77 Million EUR | 0.0% |
| 2009 Q1 | 2.77 Million EUR | -44.84% |
| 2009 FY | 11.09 Million EUR | -44.84% |
| 2008 Q3 | 5.02 Million EUR | 0.0% |
| 2008 Q1 | 5.02 Million EUR | 3.0% |
| 2008 Q2 | 5.02 Million EUR | 0.0% |
| 2008 FY | 20.1 Million EUR | 3.0% |
| 2008 Q4 | 5.02 Million EUR | 0.0% |
| 2007 Q2 | 4.88 Million EUR | 0.0% |
| 2007 FY | 19.52 Million EUR | 0.0% |
| 2007 Q1 | 4.88 Million EUR | 0.0% |
| 2007 Q4 | 4.88 Million EUR | 0.0% |
| 2007 Q3 | 4.88 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Affluent Medical SA | 25.15 Million EUR | -461.238% |
| Bluelinea Société Anonyme | 8.86 Million EUR | -1492.349% |
| Carmat SA | 96.83 Million EUR | -45.777% |
| Diagnostic Medical Systems S.A. | 37.41 Million EUR | -277.264% |
| Euromedis Groupe | 23.66 Million EUR | -496.429% |
| Ikonisys S.A. | 5.11 Million EUR | -2657.0% |
| Implanet S.A. | 10.81 Million EUR | -1205.679% |
| Median Technologies SA | 46.22 Million EUR | -205.35% |
| SpineGuard SA | 5 Million EUR | -2721.22% |
| Theraclion SA | 13.01 Million EUR | -984.441% |
| Euroapi S.A. | 684.7 Million EUR | 79.384% |
| Guerbet SA | 646.97 Million EUR | 78.182% |